(Q38123207)

29 August 2017

title

Genetic changes in nonepithelial ovarian cancer (English)

1 reference

29 August 2017

1 reference

1 reference

2

Sandrina Lambrechts

0 references

Els Van Nieuwenhuysen

series ordinal

1

object named as

Els Van Nieuwenhuysen

0 references

Diether Lambrechts

series ordinal

3

object named as

Diether Lambrechts

1 reference

29 August 2017

6

Ignace Vergote

1 reference

29 August 2017

5

Frédéric Amant

1 reference

29 August 2017

4

Karin Leunen

1 reference

29 August 2017

publication date

1 July 2013

1 reference

Expert Review of Anticancer Therapy

29 August 2017

published in

1 reference

29 August 2017

volume

13

1 reference

29 August 2017

issue

7

1 reference

29 August 2017

page(s)

871-882

1 reference

Molecular pathogenesis of granulosa cell tumors of the ovary.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Germ cell tumors of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Molecular approaches to personalizing management of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

The changing view of high-grade serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Treatment of ovarian cancer in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Management of ovarian stromal cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

The transcriptional targets of mutant FOXL2 in granulosa cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

A new target for proteasome inhibitors: FoxM1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Deciphering the role of forkhead transcription factors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Activating mutations of the stimulatory g protein in juvenile ovarian granulosa cell tumors: a new prognostic factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Expression status and mutational analysis of the PTEN and P13K subunit genes in ovarian granulosa cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Investigational agents in development for the treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Mechanisms for oncogenic activation of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Clinical trials and future potential of targeted therapy for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

The PTEN-PI3K pathway: of feedbacks and cross-talks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Targeted therapies for rare gynaecological cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

TGF-beta superfamily members and ovarian follicle development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Inhibin as a marker for granulosa-cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

The transforming growth factor-beta superfamily of receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Bone morphogenetic protein signaling transcription factor (SMAD) function in granulosa cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Transrepression of estrogen receptor beta signaling by nuclear factor-kappab in ovarian granulosa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Two G protein oncogenes in human endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Leydig cell tumors in children: contrasting clinical, hormonal, anatomical, and molecular characteristics in boys and girls

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Role of farletuzumab in epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

KIT gene mutation and amplification in dysgerminoma of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Genome-wide linkage screen for testicular germ cell tumour susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

A mini-review of familial ovarian germ cell tumors: an additional manifestation of the familial testicular germ cell tumor syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

A genome-wide association study of testicular germ cell tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Bone morphogenetic protein signalling activity distinguishes histological subsets of paediatric germ cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Dysgerminoma of the ovary in association with XY gonadal dysgenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Associations between variants in KITLG, SPRY4, BAK1, and DMRT1 and pediatric germ cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Mutation ofFOXL2in Granulosa-Cell Tumors of the Ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Follicle-Stimulating Hormone (FSH) Stimulates Phosphorylation and Activation of Protein Kinase B (PKB/Akt) and Serum and Glucocorticoid-Induced Kinase (Sgk): Evidence for A Kinase-Independent Signaling by FSH in Granulosa Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Inhibin Subunit Gene Expression in Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

Nuclear Receptor Profiling of Ovarian Granulosa Cell Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.811174

10.1586/14737140.2013.811174

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference